Intel surges more than 8% after chipmaker’s profits top expectations
NASHVILLE - Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) has appointed Steven Tahmooressi as Vice President of Marketing, the company announced Monday. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 4.04, indicating robust short-term financial health despite rapid cash utilization.
Tahmooressi, who brings over 25 years of healthcare industry experience, will lead marketing efforts for the company’s transplant and oncology assays as iMDx prepares to launch its first clinical kitted assay in 2026. The appointment comes as the company’s stock has shown strong momentum, with a 39.93% price return over the past six months and a notable 18.6% gain in the past week.
Prior to joining iMDx, Tahmooressi served as Global Brand Lead of Established Products Marketing at Astellas Pharma, overseeing transplant, urology and oncology brands. He previously held commercial roles at Abbott Laboratories and Bristol-Myers Squibb.
"As we prepare for FDA authorization of GraftAssureDx next year, we are thrilled to welcome Steven to the team," said Josh Riggs, CEO of iMDx, in a press release statement.
Tahmooressi, who joined the company in late September, has already begun meeting with customers and supported iMDx’s presence at the American Society of Histocompatibility & Immunogenetics annual meeting in Orlando.
iMDx’s initial strategic market is transplantation rejection testing through its GraftAssure family of assays. The company currently offers GraftAssureCore, a laboratory-developed test performed at its CLIA-certified lab in Nashville, and GraftAssureIQ for research use only, which became available in summer 2024.
The company is developing GraftAssureDx as a clinical molecular diagnostic test kit for distribution to hospitals, which it plans to submit for FDA authorization in 2025. The tests measure donor-derived cell-free DNA, a biomarker of transplant rejection.
iMDx estimates the addressable market for kitted transplant rejection testing at $1 billion. While the company reported impressive revenue growth of 316% in the last twelve months, InvestingPro analysis indicates the stock is currently trading near its Fair Value. Discover 12 additional exclusive ProTips and comprehensive financial metrics for IMDX with an InvestingPro subscription.
The company, formerly known as Oncocyte Corp., relocated its headquarters from Irvine, California to Nashville, Tennessee in June 2025. With a market capitalization of $110.73 million and gross profit margins of 55.7%, investors can access detailed analysis and growth projections through the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Insight Molecular Diagnostics Inc. announced the results of a study published in the American Journal of Transplantation, highlighting the effectiveness of its GraftAssure assay. The study showcased the successful monitoring of a kidney transplant patient who developed lymphoma, where the test confirmed the absence of organ rejection during CD19 CAR-T therapy. Additionally, the company launched a 5,000-patient registry to evaluate its organ rejection diagnostic test, aiming to collect approximately 50,000 samples over three years from at least 25 centers. In corporate developments, Insight Molecular Diagnostics granted stock options to key executives, including 400,000 shares to CEO Josh Riggs and 235,000 shares each to CFO Andrea James and CSO Dr. Ekkehard Schütz. Needham reiterated its Buy rating on the company, citing positive momentum in product launches and clinical development. The firm noted the progress of the GraftAssureIQ research use only test and the anticipated launch of the GraftAssureDx Kidney kitted test in mid-2026, pending FDA clearance. These recent developments reflect Insight Molecular Diagnostics’ ongoing efforts in clinical advancements and corporate growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.